Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16035550 | 0.84 | TDP1 (0.46) | LMNATSHRTDP1PIK3CDPIK3CG | |
| SCHEMBL20067789 | 0.79 | TSHR (0.51) | TP53LMNATSHRTNFNOD2 | |
| SCHEMBL15235648 | 0.76 | MAPT (0.49) | TP53LMNATSHRTNFNOD2 | |
| SCHEMBL18800195 | 0.76 | TNF (0.42) | TP53LMNATSHRTNFNOD2 | |
| SCHEMBL11358 | 0.76 | PIK3CD (0.59) | PIK3CDPIK3R1PIK3CG | |
| SCHEMBL10924 | 0.74 | CFTR (0.47) | LMNAPIK3R1MEN1KMT2APOLB | |
| SCHEMBL22238077 | 0.74 | ALDH1A1 (0.55) | TP53LMNATSHRTNFNOD2 | |
| SCHEMBL11049 | 0.72 | PIK3CD (0.71) | PIK3CDPIK3R1PIK3CG | |
| SCHEMBL20081292 | 0.71 | SMN1; SMN2 (0.44) | TP53LMNATSHRTDP1PIK3CG | |
| SCHEMBL19520444 | 0.71 | SMN1; SMN2 (0.36) | LMNATSHRPIK3CDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10028959-B2 | Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors | RESPIVERT LTD. (GB) | 2018-07-24 | — | — | US | disclosed |
| US-10028959-B2 | Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors | RESPIVERT LTD. (GB) | 2018-07-24 | — | — | US | disclosed |
| US-10028959-B2 | Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors | RESPIVERT LTD. (GB) | 2018-07-24 | — | — | US | disclosed |
| US-20180118754-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180118754-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180118754-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9834560-B2 | Compounds | RESPIVERT LTD. (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9834560-B2 | Compounds | RESPIVERT LTD. (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9834560-B2 | Compounds | RESPIVERT LTD. (GB) | 2017-12-05 | — | — | US | disclosed |
| EP-2825202-B1 | STABILIZATION OF PHARMACEUTICAL COMPOSITIONS | RESPIVERT LTD (GB) | 2017-09-06 | — | — | EP | disclosed |
| US-20130231355-A1 | QUINAZOLIN-4 (3H)- ONE DERIVATIVES USED AS P13 KINASE INHIBITORS | RESPIVERT LIMITED (US) | 2013-09-05 | — | — | US | disclosed |
| EP-2630149-A1 | QUINAZOLIN-4 (3H) -ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS | Respivert Limited (GB) | 2013-08-28 | — | — | EP | disclosed |
| EP-2491037-A1 | COMPOUNDS | Respivert Limited (GB) | 2012-08-29 | — | — | EP | disclosed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
| WO-2012052753-A1 | QUINAZOLIN-4 (3H) -ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012052753-A1 | QUINAZOLIN-4 (3H) -ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2012-04-26 | — | — | WO | disclosed |
| WO-2011048111-A1 | COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011048111-A1 | COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10028959-B2 | Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors | MAP3K13, IRAK3, MAP3K3 | TP53 979/4885LMNA 1494/4885TSHR 3943/4885 |
| US-20120208799-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | TP53 3866/4885LMNA 1817/4885TSHR 4712/4885 |
| US-20130231355-A1 | QUINAZOLIN-4 (3H)- ONE DERIVATIVES USED AS P13 KINASE INHIBITORS | MAP3K13, IRAK3, MAP3K3 | TP53 979/4885LMNA 1494/4885TSHR 3943/4885 |
| US-20180118754-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | TP53 3866/4885LMNA 1817/4885TSHR 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.